Napos drug database lurasidone porphyria?

I’m not sure which “Napos” database you mean, but here’s the general take on lurasidone and porphyria:

- Lurasidone (Latuda) is not widely reported as porphyrinogenic in standard drug safety references. There isn’t strong, consistent evidence that it triggers porphyria attacks.
- Porphyria drug safety is subtype-specific (e.g., acute intermittent porphyria vs. other types) and data are sometimes limited. So even if a drug isn’t flagged in some lists, a clinician who knows your porphyria type should confirm before starting or continuing it.

What I can do for you:
- Look up the current listing for lurasidone in the American Porphyria Foundation drug database (or the exact database you’re using) and summarize its safety rating.
- If you share a link or name of the “Napos” database, I can check that one specifically.
- If you’re starting this for a patient with porphyria, I can also outline monitoring signs to watch for and what to do if symptoms occur.

Would you like me to fetch the latest listing for lurasidone from the APF porphyria drug database or the database you have in mind? If you have the exact porphyria type (e.g., AIP, VP) or the database link, share it and I’ll tailor the info.